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Core evidence clinical impact summary for insulin glargine in the management of type 1 and type 2 diabetes mellitus

  **Outcome measure**                                       **Evidence**   **Implications**
  --------------------------------------------------------- -------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Patient-oriented evidence**                                            
  Improved quality of life                                  Substantial    Using various rating scales IG was found to be better than NPH insulin in type 1 patients, and better than pioglitazone and rosiglitazone in type 2 patients
  Improved patient satisfaction                             Substantial    Patient acceptance and wellbeing was frequently reported and confirmed in a number of RCTs
  **Disease-oriented evidence**                                            
  Effective glycemic control in type 1 diabetes             Clear          IG is at least as effective as NPH insulin
  Lower incidence of hypoglycemia in type 1 diabetes        Substantial    Trend in many studies was for a lower incidence with IG than with NPH
  Effective glycemic control in type 2 diabetes             Clear          IG was at least as effective as NPH insulin, other insulin regimens, and rosiglitazone or pioglitazone
  Lower incidence of hypoglycemia in type 2 diabetes        Clear          Significantly less hypoglycemia with IG than with NPH insulin
  **Economic evidence**                                                    
  Cost effectiveness in type 1 diabetes                     Clear          A number of RCTs and large observational studies have established the cost effectiveness of IG and confirmed its superiority over NPH insulin
  Cost effectiveness as add-on therapy in type 2 diabetes   Clear          The cost effectiveness of IG was superior to that of NPH insulin. It was also associated with lower total costs for maintaining glycemic control than add-on therapy with rosiglitazone or pioglitazone

IG, insulin glargine; NPH, neutral protamine hagedorn; RCT, randomized controlled trial.

Scope, aims, and objectives
===========================

Insulin replacement therapy has been a mainstay of treatment for patients with type 1 diabetes and a third-line alternative in patients with type 2 disease unresponsive to diet/exercise and oral antidiabetic drugs. However, traditional insulin products and more recently introduced intermediate and longer-acting preparations have not provided consistent metabolic control over a 24-hour period, while at the same time avoiding the risk of hypoglycemia (which is a significant cause of morbidity, particularly at night). The introduction of longer-acting insulin analogs that more closely mimic endogenous basal insulin patterns has been facilitated by recombinant DNA technology. In combination with the development of rapid-acting analogs that can provide mealtime cover, the newer insulin products permit greater flexibility with regards to treatment regimens and the potential to more closely mimic endogenous insulin release/blood levels ([@b68-ce-2-089]; [@b34-ce-2-089]). Insulin glargine (21A-Gly-30Ba-~L~-Arg-30Bb-~L~-Arg-human insulin; Lantus^®^) is an analog of human insulin produced by recombinant DNA technology using a nonpathogenic strain of *Escherichia coli* (K12). Once-daily subcutaneous insulin glargine has a prolonged duration of action without significant peaks of activity making it an ideal candidate as a long-acting (basal) insulin ([@b38-ce-2-089]; [@b54-ce-2-089]; [@b68-ce-2-089]; [@b55-ce-2-089]). The objective of this article is to review the current evidence concerning the effectiveness of insulin glargine in the clinical management of patients with type 1 or type 2 diabetes mellitus.

Methods
=======

PubMed ([http//www.ncbi.nlm.nih.gov/entrez/query.fcgi](http//www.ncbi.nlm.nih.gov/entrez/query.fcgi), from 1966 to date) was searched for "insulin glargine" and "HOE 901" on November 8, 2006 and updated March 10, 2007 with the limits "English language," "randomized controlled trial," "meta analysis," "humans." In addition, relevant randomized controlled clinical trials presented at the 2006 European Association for the Study of Diabetes (EASD) meeting have been included. The resulting records were then hand searched and any that did not meet the following criteria were excluded: Insulin glargine versus neutral protamine hagedorn (NPH) in ≥100 patients with type 1 diabetesInsulin glargine versus continuous insulin infusion in patients with type 1 diabetesInsulin glargine versus NPH in ≥200 patients with type 2 diabetesInsulin glargine versus premixed human biphasic insulin in patients with type 2 diabetesInsulin glargine versus oral antidiabetic drugs in patients with type 2 diabetesInsulin glargine versus insulin detemir in patients with type 1 or type 2 diabetesLarge observational studies or intensive treatment dosage titration investigations involving \>1000 patients with type 2 diabetes.

The results of the literature search and selection are shown in [Table 1](#t1-ce-2-089){ref-type="table"}.

Disease overview
================

The prevalence of diabetes mellitus has risen dramatically over the last two decades and the International Diabetes Federation (IDF) has recently estimated that there are almost 250 million people with the disease worldwide; this number is projected to exceed 380 million by the year 2025 if urgent action is not taken ([@b44-ce-2-089]). Geographically there is a wide variation in the incidence of type 1 and type 2 diabetes with the latter accounting for about 85--95% of cases in developed countries and a higher proportion in developing countries. Type 2 diabetes is largely the result of poor diet, excess bodyweight, and physical inactivity. There is also an association with age (the disease was previously termed "maturity-onset diabetes"), family history, and race/ethnicity. Worryingly, there is an increasing prevalence of type 2 diabetes in children and adolescents, which is fast being recognized as a global health problem ([@b73-ce-2-089]). Type 1 diabetes accounts for approximately 5--10% of all cases and usually starts in childhood, although onset can occur at any age. A third form of the disease is gestational diabetes, which falls outside of the scope of this review.

The burden of diabetes on healthcare systems worldwide is enormous and this is reflected in prevalence data presented by the IDF, which estimates that each year 3.8 million deaths are attributable to the disease and an even greater number of patients die from cardiovascular disease that is exacerbated by comorbid diabetes mellitus ([@b44-ce-2-089]). Additional relevant and startling statistics presented by the IDF include: diabetes is the fourth leading cause of death worldwide; it affects about 6% of the global adult population; 50% of cases remain undiagnosed (as high as 80% in some countries); it is the most frequent comorbid condition associated with kidney failure (10--20% of diabetics die of renal failure); and diabetic retinopathy is the leading cause of vision loss in adults aged 20--65 years.

Diabetes mellitus represents a heterogeneous group of metabolic disorders which are characterized by hyperglycemia as a result of severe insulin deficiency (type 1 diabetes) or defects in insulin resistance, impaired insulin secretion, and increased glucose production (type 2 diabetes). Several distinct forms of diabetes exist, resulting from a complex interaction of genetics, environmental factors, and lifestyle choices ([@b76-ce-2-089]).

Diabetes is often associated with comorbidities, such as hypertension, diabetic nephropathy, dyslipidemia, and thrombotic abnormalities such as impaired fibrinolysis and platelet hyperreactivity. When viewed as a whole they represent a milieu of risk factors that go some way to explaining why atherothrombosis (e.g. myocardial infarction, ischemic stroke) is the leading cause of mortality in patients with type 2 diabetes. They also highlight the need for a holistic approach to managing such patients with major goals that include establishing tight metabolic control, normalization of blood pressure and lipid levels, preservation of renal function, improvement of fibrinolytic activity, and cessation of smoking.

The Diabetes Control and Complications Trial Research Group ([@b17-ce-2-089]) and the UK Prospective Diabetes Study ([@b98-ce-2-089],[@b99-ce-2-089]) provide convincing evidence that tight and sustained management of glycemia (HbA~1c~ to ≤7%), using an intensive therapy regimen and regular follow-up/monitoring, reduces both the development and progression of microvascular complications. In the DCCT trial, for example, intensive therapy reduced microalbuminuria by 39%, albuminuria by 54%, and clinical neuropathy by 60%. The drawback was an increased incidence of hypoglycemia which is the single biggest barrier to administering higher dosages of insulin. Longer-term follow-up of 93% of patients included in the DCCT trial over a period of 17 years showed that intensive therapy reduced the risk of any cardiovascular disease events by 42% (*P*=0.02) and the risk of nonfatal myocardial infarction, stroke, or death from cardiovascular disease by 57% (*P*=0.02) ([@b66-ce-2-089]).

Current therapy options
=======================

The major aims of treatment for patients with type 1 or type 2 diabetes mellitus are to provide a level of glycemic control similar to that of nondiabetic individuals, to eliminate or delay the development of microvascular/macrovascular complications, and to minimize debilitating episodes of hypoglycemia and thus improve quality of life (QOL). Most treatment guidelines are now built upon the premise that tight management of blood glucose levels is pivotal to achieve optimal patient care ([@b76-ce-2-089]; [@b45-ce-2-089]). As noted previously, however, management of the diabetic patient is not simply a matter of treating the metabolic abnormality, and a holistic approach is required to minimize cardiovascular risk, diabetic nephropathy, and diabetic retinopathy. Irrespective of the type of diabetes it is important that management programs are individualized, taking into account patient characteristics and needs, as well as medical, social, nutritional, and lifestyle issues. For patients with type 1 diabetes mellitus (and therefore minimal or zero endogenous insulin secretory capacity), replacement insulin is a prerequisite for survival. Ideally, the replacement regimen should mimic a "normal" 24-hour insulin profile. In type 2 diabetes, diet, exercise, and oral antidiabetic drugs are the cornerstone of treatment. However, if glycemic control cannot be achieved using these measures, then insulin therapy should be considered, either in addition to, or in place of, oral antidiabetic drugs.

Traditional insulin products have generally proven to be suboptimal with regards to providing a consistent level of hormone for maintaining metabolic balance over a 24-hour period, while at the same time limiting the development of adverse effects such as hypoglycemia. Intermediate and longer-acting preparations have been developed allowing less-frequent administration through complexing with zinc (lente and ultralente insulin) or protamine (NPH) which helps delay the absorption of insulin. However, these products still have pronounced peaks following subcutaneous injection and may be associated with episodes of hypoglycemia. Furthermore, their duration of action may be too short to allow full 24-hour cover with once-daily administration. The introduction of longer-acting insulin analogs which more closely mimic endogenous basal insulin patterns has been facilitated by recombinant DNA technology. In combination with the development of rapid-acting analogs which can be used to provide mealtime cover, the newer insulin products permit greater flexibility regarding treatment regimens and the potential to more closely mimic endogenous insulin release/blood levels ([@b68-ce-2-089]; [@b34-ce-2-089]). Several types of human insulin and insulin analogs with different onsets and durations of activity are currently available ([Table 2](#t2-ce-2-089){ref-type="table"}).

Clinical efficacy of insulin glargine
=====================================

Clinical trials with insulin glargine in patients with diabetes mellitus should be assessed against the current background of inadequate glycemic control, especially in patients with type 2 disease ([@b1-ce-2-089]). In particular what is the level of evidence for: adequate glycemic control both short- and long-termprevention of acute episodes of hyperglycemia and hypoglycemiatolerability, treatment tolerance, and impact on QOLlonger-term reduction of microvascular and macrovascular complications; improvement in QOL and survival.

The clinical efficacy of insulin glargine administered subcutaneously once daily has been extensively investigated in patients with type 1 and type 2 diabetes mellitus treated for periods of up to 40 months. There is now available a wealth of data from large well-controlled (randomized, multicenter, parallel-group) clinical trials assessing the efficacy and tolerability of insulin glargine. Most studies evaluated its utility in basal/bolus regimens and in many trials it was compared with NPH insulin, the most widely used replacement for basal insulin. It should be noted that a drawback of a majority of these studies is that they were of open-label design; mainly as a consequence of the different appearance of the insulin preparations (insulin glargine is presented as a clear solution and NPH insulin as a turbid suspension). Clinical endpoints in the majority of trials were indicators of glycemic control such as fasting blood glucose (FBG), fasting plasma glucose (FPG), glycosylated hemoglobin (HbA~1c~), and diurnal glucose response, and tolerability (especially hypoglycemia). A growing number of trials have taken a more holistic view and measured patient satisfaction, wellbeing, QOL, and other factors impacting overall health benefit (includingseveral economic analyses). The results of pivotal clinical trials published to date are presented in [Tables 3](#t3-ce-2-089){ref-type="table"}--[7](#t7-ce-2-089){ref-type="table"}.

Clinical evidence with insulin glargine in type 1 diabetes mellitus
-------------------------------------------------------------------

Patients with type 1 diabetes require replacement insulin for survival and the current treatment regimen of choice is the basal/bolus approach, whereby a basal insulin is administered to provide 24-hour cover and supplementary rapid/short-acting insulin analogs are given at meal times to mimic physiologic prandial insulin release. The introduction of rapid-acting insulin analogs, such as insulin aspart, insulin glulisine, and insulin lispro, has greatly assisted the basal/bolus management approach and this has increased the need for an improved basal insulin to provide full 24-hour cover ([@b35-ce-2-089]). Conventional longer-acting insulin preparations, such as NPH, have not provided consistent 24-hour cover, thus necessitating twice-daily administration in some individuals. NPH insulin also has an early peak at around 4 to 6 hours following subcutaneous injection and this can be associated with hypoglycemia, a limiting and potentially dangerous adverse effect ([@b43-ce-2-089]). Insulin glargine is a recently developed, long-acting basal insulin that has been found to have a stable absorption rate without any pronounced peaks in plasma concentration, thereby providing near 24-hour cover ([@b38-ce-2-089]; [@b54-ce-2-089]; [@b68-ce-2-089]; [@b92-ce-2-089]) ([Fig. 1](#f1-ce-2-089){ref-type="fig"}).

In two of the earliest studies involving type 1 diabetes (n\>500 patients) previously treated with basal/bolus regimens for at least 2 months, insulin glargine (containing 30 or 80 mg zinc) administered once daily was more effective in lowering FPG levels than NPH insulin ([@b71-ce-2-089]; [@b86-ce-2-089]). However, these trials were of relatively short duration (4 weeks).

Clinical evidence with insulin glargine in type 1 diabetes mellitus is based on large (\>100 patients per treatment group), longer-term (≥16 weeks), multicenter RCTs (four in adults, and one in children), providing level 2 evidence ([Table 3](#t3-ce-2-089){ref-type="table"}). These studies were all open-label comparisons of once-daily insulin glargine with either once- or twice-daily NPH insulin as part of a basal/bolus regimen; the dose of basal insulin was titrated according to a target FBG level. Only outcomes related to glycemic control (including hypoglycemia) are discussed in this section; outcomes pertaining to the tolerability and safety of insulin glargine will be discussed separately.

### Glycemic control in adults: insulin glargine versus NPH insulin

[@b78-ce-2-089] compared the effects of insulin glargine once a day at bedtime and NPH insulin once or twice a day (for 16 weeks) as basal insulin treatment in patients with type 1 diabetes who were previously receiving NPH insulin for basal treatment and preprandial insulin lispro for mealtime cover. They concluded that basal insulin therapy with insulin glargine once a day appears to be as safe and at least as effective as using NPH insulin in maintaining glycemic control in patients receiving bolus insulin lispro to cover postprandial glucose surges. Insulin glargine was associated with significantly greater reductions in both FBG and FPG than NPH insulin (*P*=0.0001). Furthermore, more patients in the insulin glargine group achieved a target FBG value of \<6.7 mmol/L (29.6% vs 16.8% in NPH insulin group). There was no difference between treatment groups with regards the occurrence of hypoglycemia.

In a 28-week study, [@b81-ce-2-089] found that significant reductions in median FPG levels occurred with insulin glargine compared with NPH insulin and that reductions in capillary FBG levels, although comparable between the two groups at the end of the study, occurred much earlier with insulin glargine. At week 8, for example, mean FBG levels were reduced by 1.17 mmol/L in the insulin glargine group versus only 0.37 mmol/L in the NPH group (*P*\<0.0001). Importantly, insulin glargine was associated with fewer hypoglycemic episodes than NPH insulin. As the majority of patients with type 1 diabetes use NPH insulin twice daily, [@b40-ce-2-089] conducted a subgroup analysis using only data from patients treated with once-daily insulin glargine and twice-daily NPH insulin. The findings of this subgroup analysis support the results and conclusions from the original study. The decrease in FBG level with insulin glargine was significantly greater than with NPH insulin and, in addition, a greater percentage of patients reached a target FBG level of \<6.66 mmol/L (32.6% in insulin glargine group vs 21.3% in NPH insulin group; *P*=0.02). Once again, insulin glargine was associated with fewer episodes of symptomatic hypoglycemia.

[@b43-ce-2-089] also found that once-daily insulin glargine produces a level of glycemic control comparable to that provided by once- or twice-daily NPH insulin, without an increased risk of hypoglycemia. However, treatment satisfaction and psychologic wellbeing were also evaluated in these patients ([@b104-ce-2-089]) and showed that insulin glargine has an advantage with respect to psychologic outcomes, as people are apparently more satisfied with treatment with insulin glargine compared with NPH insulin. Improved patient satisfaction was recently confirmed in a 36-week crossover trial (a 4-week run-in followed by 16 weeks of each active treatment) comparing insulin glargine plus insulin aspart with NPH insulin plus insulin aspart in 60 type 1 diabetic patients ([@b13-ce-2-089]).

A number of smaller, well-controlled trials have confirmed the clinical benefits of insulin glargine. For example, [@b7-ce-2-089] treated type 1 diabetic patients for 6 months with prandial insulin lispro plus either once-daily insulin glargine (n=85) or twice-daily NPH insulin (n=90). Reductions in mean daily FPG during the last month of treatment were significantly greater with insulin glargine (−1.5 mmol/L) than NPH insulin (−0.5 mmol/L; *P*\<0.05). Furthermore, insulin glargine was associated with less glucose variability as documented by reduced mean amplitude of glycemic excursion (MAGE) values after 6 months' treatment. In 125 patients with type 1 diabetes treated for \>1 year and still poorly controlled (HbA~1c~ ≥8%), insulin glargine subcutaneously once daily (n=62) was compared with NPH insulin once daily (n=63) as basal insulin replacement in an intensive treatment strategy (insulin lispro was given 3 times a day at mealtimes) over a period of 30 weeks. Insulin glargine was superior to NPH insulin with respect to improving HbA~1c~, lowering FBG levels, and causing a lower incidence of moderate to severe nocturnal hypoglycemia ([@b27-ce-2-089]). [@b29-ce-2-089] compared basal/bolus regimens involving insulin glargine/insulin glulisine (premeal), insulin glargine/insulin glulisine (postmeal), and premeal regular human insulin in 860 patients with type 1 diabetes treated for 12 weeks. The premeal glulisine regimen resulted in lower HbA~1c~ levels and better postprandial glucose levels than those recorded for regular human insulin. The authors concluded that bolus insulins, such as glulisine, have more appropriate time--action profiles than regular human insulin and, in combination with newer insulin analogs such as basal insulin glargine, they may provide a more physiologic and convenient basal/bolus regimen.

Subcutaneous insulin glargine administered once daily at dinnertime has been compared with NPH insulin administered four times daily as part of intensive insulin regimens in studies of 3 months' ([@b90-ce-2-089]) and 12 months' ([@b75-ce-2-089]) duration. Both trials noted advantages for insulin glargine over NPH insulin in terms of lower daily blood glucose levels, the proportion of patients achieving blood glucose target during the day, reduction in HbA~1c~, a lower incidence of hypoglycemia, and simpler dosage schedule.

The reviewed studies provide a body of evidence highlighting the efficacy (and tolerability in terms of hypoglycemia) of insulin glargine administered subcutaneously once daily to patients with type 1 diabetes mellitus. Overall, it has been shown to be at least as effective as NPH insulin administered either once or twice daily as part of a basal/bolus treatment strategy. Indeed, this evidence was reviewed by the National Institute for Health and Clinical Excellence ([@b67-ce-2-089]), which approved its use in patients with type 1 diabetes.

### Glycemic control in adults: insulin glargine versus other antidiabetic treatments

[@b72-ce-2-089] compared twice-daily insulin detemir (n=161) and once-daily insulin glargine (n=159), both in combination with bolus insulin aspart, in patients with type 1 diabetes. Glycemic control was similar for the two treatments with the exceptions that insulin glargine produced a significantly lower FPG level (7.0 vs 7.7 mmol/L; *P*\<0.001) and insulin detemir a significantly lower predinner plasma glucose concentration (*P*\<0.05). The overall risk of hypoglycemia was also comparable for the two basal insulin therapies, although detemir was associated with significantly fewer severe (73%) and nocturnal (32%) episodes. Changes in bodyweight were not significantly different between the two groups in this 26-week trial. Both basal insulin dosage and total daily insulin dosage were higher in the insulin detemir group (0.47/0.83 vs 0.35/0.74 U/kg, respectively). Contrasting results come from an observational study recently published by [@b15-ce-2-089]. A total of 2808 patients treated with insulin glargine and 333 patients treated with insulin detemir were sourced from The Health Improvement Network (THIN) database (UK general practices) and analyzed. The results showed a trend favoring insulin glargine both in terms of glycemic control and reduced hypoglycemia.

The introduction of rapid-acting insulin analogs has aided the development of intensified insulin regimens which are designed to maintain tight glycemic control, and thus reduce longer-term complications associated with type 1 diabetes. This intensified basal/bolus approach to diabetes management is best achieved with either a continuous subcutaneous insulin infusion or multiple daily administration of NPH insulin, augmented with a rapid-acting insulin to provide mealtime cover ([@b90-ce-2-089]). The introduction of insulin glargine provides an alternative basal insulin strategy given its 24-hour profile with no distinct peaks in activity, and two recent small studies have compared basal therapy with insulin glargine with that of continuous subcutaneous infusion in patients with type 1 diabetes.

In a crossover trial of short duration (5 weeks per treatment) continuous subcutaneous insulin aspart infusion resulted in lower glycemic exposure without an increased risk of hypoglycemia, as compared with multiple daily injections of insulin aspart/insulin glargine ([@b41-ce-2-089]). The authors noted that for patients receiving continuous infusion therapy, multiple injections with insulin aspart/insulin glargine is a viable option for periods when the pump cannot be used (for example because of a pump malfunction, skin problems, physical activity, etc). A similar conclusion was reached by [@b6-ce-2-089] in a study involving 38 patients with type 1 diabetes who switched from continuous subcutaneous infusion with insulin lispro to multiple daily injections with insulin glargine and insulin lispro. In this trial, insulin glargine was administered at a dosage equal to (1:1) or 1.2 times (1:1.2) the mean total daily continuous subcutaneous infusion basal insulin dose, and the former (1:1) was recommended as the preferred choice for pump-free periods since it provided effective glycemic control and a lower propensity for causing hypoglycemia.

### Studies assessing insulin glargine administration regimens

A number of studies have assessed issues relating to timing of administration, titration, and dosage. The AT.LANTUS Study Group reported that in a large population of patients with long-standing, suboptimally controlled, type 1 diabetes (n=2442), two insulin glargine regimens (insulin glargine increased in increments of at least 10%, but not \>4 U; or insulin glargine increased in increments of 1--6 U) produced equivalent statistically significant improvements in glycemic control with low rates of severe hypoglycemia ([@b31-ce-2-089]). In terms of timing of administration, [@b35-ce-2-089] reported no clinically relevant differences in efficacy or safety with insulin glargine administered before breakfast, before dinner, or at bedtime. Likewise, [@b32-ce-2-089] observed no clinically relevant differences in efficacy or tolerability in type 1 diabetic patients administered insulin glargine at dinnertime (n=589) or bedtime (n=589) for 26 weeks.

Some clinicians have observed predinner increases in blood glucose levels when insulin glargine is injected at bedtime, and [@b4-ce-2-089] have suggested that it may be better to administer insulin glargine at lunchtime or dinnertime to avoid this effect. The same group ([@b5-ce-2-089]) assessed once (dinnertime) and twice (half doses administered at breakfast and dinnertime) daily administration of insulin glargine in a crossover study involving 20 patients with type 1 diabetes treated for 4 weeks. The twice-daily regimen resulted in lower blood glucose levels after breakfast, lunch, and before dinner, and it was also associated with lower mean 24-hour blood glucose levels (7.1 vs 8.8 mmol/L; *P*=0.031) and less within-day variability in blood glucose levels (*P*=0.044). The authors concluded that for patients who experience late afternoon increases in blood glucose levels, twice-daily insulin glargine is a suitable alternative which does not require an increase in insulin dosage nor does it negatively impact treatment satisfaction.

### Glycemic control in children

The principle of achieving tight metabolic control in patients with type 1 diabetes so as to delay the onset and slow the progression of both microvascular and macrovascular complications applies as much to children as it does to adults ([@b18-ce-2-089]). However, adequate control is difficult in younger patients due to endocrine, behavioral, and social factors. As a result, less than one-third of children and adolescents being treated for diabetes are considered to be well controlled ([@b65-ce-2-089]).

[@b91-ce-2-089] compared the efficacy of insulin glargine with NPH insulin in children and adolescents aged 5--16 years with type 1 diabetes mellitus. Although there was no difference between the insulin glargine and NPH insulin treatment groups with respect to baseline-to-endpoint change in HbA~1c~ levels, significant reductions in FBG levels were observed with insulin glargine (−1.29 mmol/L) compared with NPH insulin (−0.68 mmol/L; *P*=0.02). In addition, a higher percentage of patients using insulin glargine (43.9%) reached the target FBG level at endpoint compared with NPH insulin (39.0%). The frequency of symptomatic hypoglycemia was similar between the two groups despite a nonsignificant trend to fewer episodes of severe hypoglycemia and severe nocturnal hypoglycemia in those treated with insulin glargine.

These findings are supported by a recent smaller study by [@b12-ce-2-089], who compared the efficacy of once-daily insulin glargine (n=85) with twice-daily NPH or lente (n=90) as basal therapy in pediatric patients with type 1 diabetes treated with a multiple daily injection regimen including premeal insulin lispro. Despite only a small reduction in mean HbA~1c~ from baseline to endpoint in both groups, they reported that in patients with a high baseline HbA~1c~, insulin glargine produced a significantly greater reduction in mean HbA~1c~ than NPH/lente. Patients treated with insulin glargine also showed less blood glucose variability assessed during continuous blood glucose monitoring. Rates of hypoglycemia were comparable between the two treatment groups.

A retrospective analysis of the medical records of 64 children with type 1 diabetes aged under 6 years documented a decrease in severe hypoglycemia, particularly at night, during the first 6 months of therapy with insulin glargine ([@b19-ce-2-089]). In the 6 months before the study period, 16 severe hypoglycemic events were observed compared with three during the first 6 months of insulin glargine therapy (12 night-time severe hypoglycemic events were noted prestudy and only one during treatment with insulin glargine). Similar results were recorded in a group of 34 preschool children (aged 2.6--6.3 years) who were treated with a flexible multiple-day insulin regimen (premeal lispro plus bedtime glargine) for at least 1 year ([@b3-ce-2-089]). HbA~1c~ and the incidence of severe hypoglycemia were significantly reduced compared with previous treatment (premeal lispro plus twice-daily ultralente) and the best results were achieved in children with normal bodyweight. Given the adverse impact severe hypoglycemia may have on the developing brain in young children, the authors recommend that further controlled studies should be undertaken to confirm these clinically important findings.

Another retrospective case analysis assessed the effectiveness of insulin glargine in patients under 21 years (range 2--20 years) with considerably higher mean HbA~1c~ levels at baseline (9.7±1.9%) despite previously receiving NPH insulin ([@b36-ce-2-089]). The majority of patients had type 1 diabetes and HbA~1c~ was significantly decreased from a baseline of 9.5% to 8.6% (*P*\<0.001) following 9 months' treatment with insulin glargine. This reduction was associated with a significant decrease in hypoglycemia (12.2% to 10.7%; *P*=0.004), but surprisingly little change in mean blood glucose levels. [@b14-ce-2-089] also documented a significant reduction in HbA~1c~ levels following 6 months' therapy in 80 patients aged 2 to 19 years with type 1 diabetes treated with insulin glargine plus short-acting (regular human) insulin or a rapid-acting analog to provide mealtime cover. HbA~1c~ fell from 7.63% to 7.14% (*P*\<0.001) in the total cohort and this reduction was associated with decreased FBG (161 to 150 mg/dL; *P*=0.05) and a lower incidence of severe hypoglycemia (0.18 to 0.11 events/patient; not significant). In a study of shorter duration (16 weeks), [@b22-ce-2-089] reported a significantly (*P*\<0.05) greater reduction in HbA~1c~ levels following continuous subcutaneous insulin infusion (8.1% to 7.2%) compared with a multiple daily injection regimen including insulin glargine (8.2% to 8.1%) in 32 young patients (8--21 years) with type 1 diabetes treated for 16 weeks. However, in a similarly designed study involving 32 type 1 diabetic children (mean age 12.5 years) treated for 2 years with continuous subcutaneous insulin infusion or a multiple daily injection regimen including insulin glargine, the two treatment approaches were found to be equally effective and well tolerated ([@b28-ce-2-089]).

### Insulin dosage

In all five of the studies summarized in [Table 3](#t3-ce-2-089){ref-type="table"}, the daily basal insulin dose tended to increase from baseline to endpoint for those patients in the NPH insulin treatment group. In comparison, there was a decrease in those receiving insulin glargine and this was almost entirely due to a reduction in the daily basal insulin dose seen in those patients previously using a twice-daily NPH insulin regimen. This fall in daily basal insulin dose was associated with a small increase in total daily bolus dosage (short- or rapid-acting insulins). It has been suggested that this need for less basal insulin when using insulin glargine, along with the lower FBG levels it results in, may allow for more aggressive bolus therapy with fast-acting insulins, and this may further help improve glycemic control in patients with type 1 diabetes ([@b40-ce-2-089]).

Clinical evidence with insulin glargine in adults with type 2 diabetes mellitus
-------------------------------------------------------------------------------

Insulin therapy in patients with type 2 diabetes mellitus is generally reserved for patients unresponsive to management with diet, exercise, and oral antidiabetic drugs. This is reflected in clinical trials involving insulin glargine since inclusion criteria usually specified patients with type 2 diabetes who did not achieve good metabolic control (usually HbA~1c~ \>7--7.5%) despite being treated with one or more oral antidiabetic agents. Clinical assessment of insulin glargine in patients with type 2 diabetes has included the following: Large RCTs (level 2 evidence) and a meta analysis (level 1 evidence) versus NPH insulinSeven RCTs against premixed biphasic insulins (level 2 evidence)Two randomized clinical trials with exenatide (level 2 evidence)Randomized clinical trials versus rosiglitazone (n=4) and pioglitazone (n=1) (both level 2 evidence)A large observational study from everyday practice in Germany involving \>12 000 patients (level 4 evidence)Two large randomized controlled "treatment approach" clinical trials (level 2 evidence) assessing different treatment algorithms.

### Glycemic control in adults: insulin glargine versus NPH insulin

The emphasis in this section of the review is given to randomized, controlled clinical trials which compared insulin glargine with NPH insulin and included \>200 patients with type 2 diabetes per treatment group ([Table 4](#t4-ce-2-089){ref-type="table"}). All studies included insulin-naïve patients except the studies of [@b87-ce-2-089] and [@b59-ce-2-089]; the latter is a follow-up of the study reported by [@b105-ce-2-089], but includes data from an additional 144 patients who had previously received insulin therapy.

The results from six of these large controlled trials (level 2 evidence) comparing subcutaneous insulin glargine with subcutaneous NPH insulin show that over a period of up to 1 year, both insulin glargine and NPH insulin produced clinically significant improvements in glycemic control with some trials reporting high response rates. For example [@b84-ce-2-089] noted that the majority of patients (∼60%) attained an HbA~1c~ level of 7% or less with both insulin glargine and NPH insulin. Similarly [@b23-ce-2-089] reported that approximately 50% of patients achieved an HbA~1c~ level of \<7.5%. [@b69-ce-2-089] observed a lower overall response rate in terms of HbA~1c~ (\<7.5%) in Asian patients treated with insulin glargine (38.1%) or NPH insulin (30.3%). However, a greater percentage of patients (62.3% and 58.7%, respectively) achieved a target FBG level of ≤120 mg/dL.

Interestingly, [@b26-ce-2-089] found that insulin glargine and NPH insulin administered at bedtime reduced HbA~1c~ to below 7.5% in approximately one-third of patients, but a significantly greater number of patients responded when insulin glargine was administered before breakfast (43%). In this study HbA~1c~ levels improved by a statistically greater extent with morning insulin glargine (−1.24) than with either NPH insulin (−0.84; *P*\<0.001) or bedtime insulin glargine (−0.96; *P*=0.008). Insulin glargine administered before breakfast resulted in a greater decrease in mean daily blood glucose levels (determined during diurnal blood glucose testing) compared with both bedtime NPH (*P*\<0.001) and bedtime insulin glargine (*P*=0.002). [@b105-ce-2-089] reported a significantly greater decrease in blood glucose concentrations before and after dinner in patients treated with insulin glargine compared with those treated with NPH insulin (both drugs administered at bedtime). Similarly, [@b69-ce-2-089] observed lower glucose levels postdinner in the insulin glargine group (236 vs 249 mg/dL; *P*\<0.05), and also a decrease in mean daily blood glucose levels (−94 vs −80 mg/dL; *P*=0.018).

A consistent and important clinical finding in all of these large trials was that insulin glargine resulted in a lower incidence of nocturnal hypoglycemia than that associated with NPH insulin. The authors of all these large randomized clinical trials concluded that, compared with NPH insulin, once-daily insulin glargine produced equivalent glycemic control (in two studies there were some significant changes favoring insulin glargine), but the newer insulin analog had the significant clinical advantage of causing less nocturnal hypoglycemia---a frequent barrier to starting insulin therapy in patients with type 2 diabetes mellitus.

These findings have been augmented by a meta analysis (level 1 evidence) of four of these trials ([@b105-ce-2-089]/[@b59-ce-2-089]; [@b87-ce-2-089]; [@b26-ce-2-089]; [@b84-ce-2-089]) which is summarized in [Table 5](#t5-ce-2-089){ref-type="table"} ([@b88-ce-2-089]). In this analysis, involving \>1000 patients per treatment group, insulin glargine and NPH insulin produced equivalent glycemic control as determined by the number of patients achieving HbA~1c~ levels ≤7.0%, although insulin glargine was associated with significantly lower FPG levels (8 vs 9 mmol/L; *P*=0.023). In line with the conclusions reached by the individual clinical trials, the main finding of clinical consequence from the meta analysis was the significantly lower risk of hypoglycemia occurring with insulin glargine. The risk reduction was 59% for severe nocturnal hypoglycemia (*P*=0.0231), 46% for severe hypoglycemia (*P*=0.0442), 26% for nocturnal hypoglycemia (*P*\<0.0001), and 11% for overall documented hypoglycemia (*P*=0.0006).

Studies involving smaller numbers of patients have produced comparable results to the large studies described above ([@b42-ce-2-089]; [@b25-ce-2-089]; [@b106-ce-2-089]). Furthermore, at a titration target of FBG ≤5.5 mmol/L, [@b96-ce-2-089] noted that bedtime and morning regimens of insulin glargine were equivalent in terms of achieving good glycemic control without any significant difference in hypoglycemia. In the longest study to date (an extension of the large study reported by [@b105-ce-2-089] and [@b59-ce-2-089]), 198 type 2 diabetic patients received subcutaneous insulin glargine for up to a further 28 months in an open noncontrolled clinical study. The longer-term efficacy (assessed by HbA~1c~ levels) and safety of insulin glargine was confirmed in this trial ([@b49-ce-2-089]).

An interesting study reported by [@b30-ce-2-089] is the Canadian Insight (Implementing New Strategies with Insulin Glargine for Hyperglycemia Treatment) Study. This trial assessed the "early" introduction of insulin glargine in 405 patients with type 2 diabetes with an HbA~1c~ of ≥7.5%, but not receiving full doses of oral antidiabetic therapy. Two hundred and six patients were randomized to receive insulin glargine and 199 to continue usual dose titration with oral therapy (to a FPG of ≤5.5 mmol/L and an HbA~1c~ of ≤7%) for a period of at least 6 months. Compared with usual therapy, patients receiving insulin glargine achieved significantly better glycemic control as evidenced by greater decreases in HbA~1c~ (−1.55 vs −1.25%; *P*=0.005) and FPG (−3.89 vs −2.31 mmol/L; *P*=0.0001), and the frequency of achieving two consecutive HbA~1c~ measurements ≤6.5% (insulin glargine patients were 1.7 times more likely to reach this primary endpoint; *P*=0.049). Insulin glargine therapy was also associated with an improved lipid profile \[decreased non-high-density lipoprotein cholesterol (*P*=0.02) and triglycerides (*P*=0.02)\] and greater increases in treatment satisfaction (*P*=0.045), but increased bodyweight (+1.9 kg; *P*\<0.0001).

The above findings from well-controlled clinical trials have recently been augmented by a 20-month observational study (level 4 evidence) involving \>12 000 type 2 diabetic patients poorly controlled by oral therapy from everyday practice in Germany ([@b93-ce-2-089]). The mean HbA~1c~ level was 8.7% at baseline (n=11 511), and following the addition of insulin glargine 7.2% at 3 months (n=11 296), 7.0% at 9 months (n=6031), and 7.0% at 20 months (n=2374).

In the above studies, changes in bodyweight were generally similar for insulin glargine and NPH insulin with two studies reporting an advantage for glargine ([@b87-ce-2-089]; [@b25-ce-2-089]) but others noting nonsignificant reductions with NPH insulin ([@b26-ce-2-089]; [@b84-ce-2-089]). In the large observational study reported by [@b93-ce-2-089] body mass index decreased slightly from a mean of 29.0 kg/m^2^ at baseline to 28.5 kg/m^2^ after 9 months of insulin glargine treatment.

### Glycemic control in adults: insulin glargine versus other antidiabetic treatments

Studies comparing once-daily insulin glargine with premixed biphasic insulins in patients with type 2 diabetes mellitus poorly controlled with oral antidiabetic drugs (and in one study plus insulin; [@b57-ce-2-089]) generally reported improved metabolic control with all of the insulin regimens ([Table 6](#t6-ce-2-089){ref-type="table"}). In terms of which regimen is best with respect to improving glycemic control the results have varied, but there is a trend toward better glycemic control, increased insulin dosage, and an increased incidence of hypoglycemia with the biphasic preparations, but this has not been the case in all studies.

For example, [@b47-ce-2-089] found that once-daily (morning) insulin glargine in combination with glimepiride and metformin reduced FBG and HbA~1c~ levels, and was associated with significantly lower incidence of hypoglycemia compared with human insulin (30% regular, 70% NPH) alone. Furthermore, these advantages were also apparent in a subgroup of 130 patients aged ≥65 years ([@b48-ce-2-089]). In contrast, in the INITIATE study, biphasic insulin aspart 30/70 in combination with oral antidiabetic drugs produced a significantly greater reduction in HbA~1~c levels than insulin glargine once daily (at bedtime) plus oral antidiabetic drugs, but this was associated with a significantly greater increase in biphasic insulin dosage (*P*\<0.05), weight gain (*P*\<0.01), and incidence of minor hypoglycemia (*P*\<0.05) ([@b79-ce-2-089]). Similar findings were noted in a subpopulation of patients who were not receiving thiazolidinedione treatment in the original study ([@b80-ce-2-089]). Comparable results with biphasic insulin aspart 30/70 (plus metformin; n=128) versus insulin glargine (plus glimepiride; n=127) were reported by [@b50-ce-2-089] in a randomized trial in which patients were treated for 26 weeks. Biphasic insulin aspart 30/70 resulted in a lower mean plasma prandial glucose increment (calculated from a 7-point plasma glucose profile), but increased minor hypoglycemia.

In two crossover trials involving relatively small numbers of patients with type 2 diabetes poorly controlled by oral antidiabetic drugs ([@b56-ce-2-089]) or by intermediate insulin with or without oral antidiabetic drugs ([@b57-ce-2-089]), daily insulin glargine (at bedtime) was compared with biphasic insulin lispro 25/75. The authors concluded that biphasic insulin lispro 25/75 was a more effective treatment option because it resulted in a greater decrease in HbA~1c~ levels, a higher number of HbA~1c~ ≤7% responders, and more patients achieving morning and evening blood glucose targets. However, it should be noted that insulin glargine produced a significantly greater decrease in FBG levels, and more FBG ≤7 mmol/L responders. Insulin dosage was not increased as much in the insulin glargine group (significantly so in the most recent study; [@b57-ce-2-089]). Changes with respect to hypoglycemia favored insulin glargine in one study ([@b56-ce-2-089]) and biphasic insulin lispro in the other ([@b57-ce-2-089]). The same group recently reported results from a crossover trial involving 20 patients with type 2 diabetes inadequately controlled by metformin and/or a sulfonylurea who received additional treatment with biphasic insulin lispro 25/75 or insulin glargine ([@b85-ce-2-089]). After 3 months' treatment, 24-hour test meal assessments demonstrated that biphasic insulin lispro 25/75 was associated with lower mean postprandial glucose and 24-hour plasma glucose, but similar FPG. It was also associated with an increase in mild hypoglycemia. Intensive treatment with biphasic insulin lispro (injecting lispro 50/50 before breakfast and lunch, and lispro 25/75 before dinner) produced better overall glycemic control (HbA~1c~ and postprandial blood glucose levels) than insulin glargine, but it was associated with an increased incidence of mild hypoglycemia ([@b46-ce-2-089]).

Recent comparative studies in patients with poorly controlled type 2 diabetes demonstrated the following results with once-daily insulin glargine: Insulin glargine was as effective as twice-daily exenatide 5--10 mcg twice daily, and was associated with a significantly lower incidence of gastrointestinal side effects ([@b37-ce-2-089]; [@b94-ce-2-089]). In the latter study insulin glargine and exenatide demonstrated comparable improvements in treatment satisfaction.In four clinical trials insulin glargine and rosiglitazone produced similar levels of glycemic control in double- or triple-therapy regimens ([@b89-ce-2-089]; [@b97-ce-2-089]; [@b83-ce-2-089]; [@b101-ce-2-089]). [@b89-ce-2-089] reported greater reductions in HbA~1c~ levels in patients whose baseline value was ≥9.5%, while [@b101-ce-2-089] noted statistically significant improvements in QOL measures for insulin glargine compared with rosiglitazone.Insulin glargine improved glycemic control and diabetes-related QOL compared with pioglitazone ([@b63-ce-2-089]).In older patients (≥60 years) with poorly controlled type 2 diabetes, intensive therapy with continuous subcutaneous infusion or multiple daily injections (insulin lispro/insulin glargine) resulted in an HbA~1c~ \<7% response rate of approximately 80% ([@b39-ce-2-089]).Insulin glargine and prandial insulin lispro produced similar reductions in HbA~1c~ levels, but insulin glargine was associated with significantly lower FBG levels, nocturnal blood glucose, and a lower incidence of hypoglycemia (as well as fewer injections and less self-monitoring of blood glucose levels), whereas insulin lispro produced better control of postprandial blood glucose levels ([@b8-ce-2-089]).Based on findings from an observational analysis using data from UK general practices, insulin glargine (n=2875) tended to produce slightly improved diabetes control than insulin detemir (n=361) and less hypoglycemia ([@b15-ce-2-089]).

### Glycemic control in adults: "treatment approach"

In a large clinical trial, [@b16-ce-2-089] compared two treatment approaches with insulin glargine in \>4000 patients with type 2 diabetes. As in most other clinical trials insulin dosage was titrated to specific FBG targets and the aim of this trial was to compare investigator/physician-led titration with patient self-managed titration over a 24-week period. Interestingly, the self-managed approach to insulin glargine dose titration resulted in higher dosages of insulin being administered and this was associated with better glycemic control (as measured by HbA~1c~ and FBG levels) and an increase in symptomatic hypoglycemia (but not severe or nocturnal episodes).

More recently, [@b52-ce-2-089] assessed glycemic control using a combination of active versus usual algorithmic titration approaches, and point-of-care versus laboratory measurement of HbA~1c~. This trial included \>7500 patients with type 2 diabetes treated for a period of 24 weeks; the best results in terms of lowering of FBG (self-monitored) and proportion of patients with HbA~1c~ levels \<7% was achieved with active titration and point-of-care monitoring. Active titration was defined as weekly patient contact (telephone, fax, email) to review general wellbeing, review glucose values, and reinforce insulin titration; this was in addition to the usual titration that occurred every 6 weeks.

Quality of life
---------------

Diabetes mellitus is a chronic, often debilitating disease which can affect many aspects of day-to-day life. In its most severe forms, when poorly controlled, the disease is associated with longer-term microvascular (retinopathy, neuropathy, and nephropathy) and macrovascular complications. Treatment should be multifactorial so as to achieve optimal control of the underlying disease, and to alleviate symptoms and minimize risk of long-term complications. This in itself may impact the patient's wellbeing, but it is further confounded by the side effects of intensive glycemic treatment such as potentially disabling hypoglycemia, weight gain, and increased cost to the patient.

In clinical trials a number of authors commented on the positive impact of insulin glargine on patient wellbeing and its acceptance by patients ([@b91-ce-2-089]; [@b22-ce-2-089]; [@b14-ce-2-089]; [@b39-ce-2-089]; [@b43-ce-2-089]; [@b8-ce-2-089]; [@b23-ce-2-089]; [@b63-ce-2-089]; Chaterjee et al. 2007). As part of a formal analysis of treatment satisfaction and physiologic wellbeing, [@b104-ce-2-089] assessed 517 patients with type 1 diabetes participating in an RCT in Europe using the Diabetes Treatment Satisfaction Questionnaire (DTSQ) and the Well-Being Questionnaire (W-BQ). After 28 weeks' therapy, insulin glargine produced an improvement in "treatment satisfaction" which was significantly superior to that produced by NPH insulin (difference between treatments was 1.83 points; *P*\<0.001). Both insulin preparations decreased "perceived frequency of hyperglycemia" scores but the effect was significantly more pronounced with insulin glargine (*P*=0.037). Psychologic wellbeing scores were improved equally by insulin glargine and NPH insulin. These findings were augmented by those of [@b58-ce-2-089] who reported significant improvements in Well-being Enquiry for Diabetics (WED) related to discomfort (*P*=0.02), impact (*P*=0.0002), and total score (*P*=0.0005) in 40 type 1 diabetic patients switched from NPH insulin to insulin glargine because of suboptimal control. The health-related quality of life (HRQL)-WED questionnaire was undertaken at 6--8 months after switching to insulin glargine, at which stage there was a perceived lower risk of hypoglycemia and less problems in daily life with insulin glargine and, importantly, HbA~1c~ was reduced by 0.7% (*P*\<0.0001 vs baseline).

Similarly, in a general practice study involving 135 patients with type 1 diabetes and 180 patients with type 2 diabetes, insulin glargine produced significant improvements in HRQL in a subset of 50 patients who completed the survey ([@b24-ce-2-089]). Statistically significant improvement was recorded for scores relating to total symptoms (34.8%; *P*\<0.0001), total symptom distress (42.6%; *P*\<0.0001), overall wellbeing (*P*=0.002), and emotional wellbeing (*P*=0.003) compared with baseline values. These improvements in QOL were associated with significantly improved glycemic control as assessed by HbA~1c~ levels (reduced by 0.28±1.47, *P*=0.03, in type 1 diabetic patients; and reduced by 0.6±1.51, *P*\<0.0001, in type 2 diabetic patients).

[@b63-ce-2-089] assessed HRQOL in 230 type 2 diabetic patients treated with insulin glargine (n=112) or pioglitazone (n=118), as add-on therapy, over a period of 48 weeks. Insulin glargine produced greater improvement in 17 of 20 HRQL measures from baseline to week 48 compared with pioglitazone. The results were statistically significant (*P*\<0.05) for domains measuring psychologic distress related to hyperglycemic symptoms, fatigue, and total symptom-related distress. Using multivariate analysis insulin glargine was associated with significantly better outcomes for hyperglycemic and ophthalmologic symptoms, and for psychologic distress related to fatigue, hyperglycemic, hypoglycemic, ophthalmologic, and cardiovascular symptoms. Similar findings were recently reported by [@b101-ce-2-089] in a randomized, multicenter study comparing insulin glargine and rosiglitazone as add-on therapy in 217 patients with poorly controlled type 2 diabetes despite being treated with a sulfonylurea plus metformin. The two drugs were equally effective in terms of improving glycemic control, but insulin glargine produced significantly greater benefits over rosiglitazone in the Diabetes Symptom Checklist-Revised (DSC-R) total symptom score (*P*=0.005), total distress score (*P*=0.03), and individual domain scores for mood symptoms (*P*=0.007), ophthalmologic symptoms (*P*=0.007), ophthalmologic distress (*P*=0.013), fatigue distress (*P*=0.033), and Short Form-36 (SF-36) perception of general health (*P*=0.047). Finally, in a randomized, multicenter, 26-week clinical trial once-daily insulin glargine (n=227) and twice-daily exenatide (n=228) were found to be equally efficacious in terms of glycemic control and improving QOL as assessed by DSC-R, DTSQ, and the SF-36 vitality subscale ([@b94-ce-2-089]).

Tolerability and safety of insulin glargine
-------------------------------------------

According to the Physicians' Desk Reference (PDR) the adverse reactions most commonly associated with insulin glargine include: body as a whole---allergic reactionskin and appendages---injection site reaction, lipodystrophy, pruritus, rashother---hypoglycemia.

In one of the largest studies published to date, 7893 patients with type 2 diabetes were randomized to treatment with insulin glargine (comparing active vs usual algorithmic titration, and point-of-care vs laboratory measurement of HbA~1c~) for a period of 24 weeks ([@b52-ce-2-089]). No unexpected findings in the frequency or spectrum of adverse events were observed in this trial, with hypoglycemia being the most frequent serious adverse event ([Table 7](#t7-ce-2-089){ref-type="table"}). Similar results were reported by [@b16-ce-2-089] in a study involving almost 5000 patients with type 2 diabetes treated with insulin glargine for 24 weeks. In this study 11% of patients reported an adverse event which was considered possibly related to insulin glargine and the majority of these were mild injection site reactions.

In the longest clinical trial reported thus far, patients with type 2 diabetes were treated with insulin glargine or NPH insulin for an initial 1-year period ([@b59-ce-2-089]) and followed for a further 28 months ([@b49-ce-2-089]). As can be seen in [Table 8](#t8-ce-2-089){ref-type="table"}, the incidence of adverse events was similar between the two treatment groups. During the extension study, insulin glargine was well tolerated with only four patients reporting adverse events that were considered possibly related to treatment ([@b49-ce-2-089]).

[@b91-ce-2-089] reported on the tolerability of insulin glargine and NPH insulin as part of basal/bolus regimens administered for 6 months to 349 children/adolescents (aged 5--16 years) with type 1 diabetes. Both drugs were well tolerated, but there were fewer serious adverse events in the insulin glargine group (5.8% vs 13.7%). None required discontinuation of therapy.

Finally, two clinical trials compared insulin glargine as third-line therapy with rosiglitazone ([@b89-ce-2-089]) or exenatide ([@b37-ce-2-089]) in type 2 diabetic patients with poor glycemic control. Adverse events possibly related to treatment were significantly more frequent with rosiglitazone (28.6% vs 6.7%; *P*\<0.0001). Compared with exenatide, insulin glargine was associated with a significantly lower incidence of gastrointestinal side effects, most notably nausea (8.6% vs 57.1%; *P*\<0.001), and vomiting (3.7% vs 17.4%; *P*\<0.001). Since nausea and vomiting may predispose diabetic patients (usually type 1) to ketoacidosis, this is clearly an important finding, Separately, one case of nausea and vomiting has been reported in a type 1 diabetic patient treated with insulin glargine ([@b19-ce-2-089]).

Within the published clinical literature the most commonly discussed tolerability and safety issues associated with the treatment of diabetic patients with insulin include: symptomatic hypoglycemia, injection site reactions, possible immunogenicity, effects on bodyweight, and possible progression of retinopathy. These will be discussed separately based mainly on the evidence of the large clinical trials cited in [Tables 3](#t3-ce-2-089){ref-type="table"} to [6](#t6-ce-2-089){ref-type="table"}.

### Symptomatic hypoglycemia

Aggressive titration of insulin to achieve tight glycemic control is hampered by the potential occurrence of hypoglycemic episodes. Indeed, hypoglycemia is the most frequent acute complication of intensive insulin therapy in patients with type 1 diabetes ([@b81-ce-2-089]).

The incidence of symptomatic and/or nocturnal and severe hypoglycemia was reviewed in the Clinical efficacy section ([Tables 3](#t3-ce-2-089){ref-type="table"}, [4](#t4-ce-2-089){ref-type="table"}, and [6](#t6-ce-2-089){ref-type="table"}). While not all clinical trials demonstrated a statistically significant advantage for insulin glargine over comparator insulin regimens (mostly NPH insulin) in patients with type 1 or type 2 diabetes, there is a clinically significant trend in favour of glargine. Thus, in the 17 large controlled trials reviewed in [Tables 3](#t3-ce-2-089){ref-type="table"}, [4](#t4-ce-2-089){ref-type="table"}, and [6](#t6-ce-2-089){ref-type="table"}, 14 trials identified a significantly lower occurrence of hypoglycemia with insulin glargine; two trials noted no difference between insulin glargine and NPH insulin. The final trial reported a lower incidence of nocturnal hypoglycemia with premixed biphasic insulin lispro 25/75 despite a lower incidence of symptomatic hypoglycemia with insulin glargine ([@b57-ce-2-089]).

Overall, there appears to be a clinically relevant trend toward fewer hypoglycemic episodes (including nocturnal hypoglycemia) with insulin glargine compared with more traditional insulins such as NPH. The low rate of hypoglycemic episodes has been confirmed in large studies (involving a total of \>10 000 patients) comparing different treatment algorithms of insulin glargine in patients with type 2 diabetes ([@b16-ce-2-089]; [@b52-ce-2-089]) and in a meta analysis comparing insulin glargine with NPH insulin ([@b88-ce-2-089]).

### Injection site reactions

Apart from hypoglycemia, the most common adverse event reported in clinical trials published to date has been a reaction at the site of injection; this applies to comparator insulin products as well as insulin glargine. The type of injection site reaction has been further subdivided to include: pain hemorrhage, mass, or "reaction." Reviewing all the large clinical trials included in [Tables 3](#t3-ce-2-089){ref-type="table"}, [4](#t4-ce-2-089){ref-type="table"}, and [6](#t6-ce-2-089){ref-type="table"} revealed no clinically significant trend with regards to this adverse effect, with all authors concluding that the episodes were mild and did not require discontinuation of treatment. In four trials, injection site pain was more common in patients treated with insulin glargine that in those receiving NPH insulin ([@b78-ce-2-089]; [@b81-ce-2-089]; [@b87-ce-2-089]; [@b40-ce-2-089]), but in all cases the effect was considered mild and once again did not require discontinuation of treatment. There is some evidence that with time and perhaps developing a better injection technique (regular rotation of the injection site), local reactions are not a clinical concern. For example, [@b59-ce-2-089] reported an incidence of injection site reactions of 3.1% in insulin glargine-treated patients (n=289; one patient discontinued therapy) and 3.9% in NPH insulin-treated patients (n=281). A total of 239 patients from the insulin glargine group entered a long-term follow-up study of up to 28 months' duration and no adverse events concerning the injection site were recorded; specifically there were no reports of pain ([@b49-ce-2-089]).

In a study involving 349 children/adolescents (aged 5 to 16 years) treated with insulin glargine or NPH insulin for 6 months there was no difference between the two treatments with respect to injection site adverse reactions classified as atrophy, fibrosis, hemorrhage, mass, pain, or reaction ([@b91-ce-2-089]). It has been speculated that patients perceive more pain during subcutaneous administration of acidic solutions (such as insulin glargine; pH 4.0). In this regard [@b51-ce-2-089] compared insulin glargine (acidic) with NPH (neutral) in 112 children/adolescents aged 7--21 years with type 1 diabetes. There was no significant difference in pain perception between the two treatments and pain scores were also very similar to those associated with the injection of short-acting regular insulin.

### Retinopathy

Diabetes mellitus is a leading cause of blindness in the adult population and the most effective treatment is prevention by means of tight control of blood glucose levels and blood pressure ([@b76-ce-2-089]). Regular eye examinations are essential for all patients with diabetes mellitus (type 1 or 2) and careful monitoring is crucial when new therapies are introduced. Initially it was thought that the high binding affinity of insulin glargine for insulin-like growth factor (IGF)-1 receptors may adversely impact the progression of retinopathy in diabetic patients ([@b10-ce-2-089]). However, clinical studies have not observed any such changes.

The most extensive data for insulin glargine derives from a retrospective analysis of clinical trials involving data from 2207 patients who were treated with insulin glargine or NPH insulin for 28 to 52 weeks ([@b62-ce-2-089]). Overall, the panel of experts who reviewed the data concluded that there was no increased risk toward retinopathy with insulin glargine compared with NPH insulin. While individual studies reported higher rates of new macular edema and a ≥3-step change in progression of retinopathy (both using photographic methods) with insulin glargine, there were no reports of optic disc swelling in any of the treatment groups ([@b62-ce-2-089]). In published studies reviewed in the clinical sections, there has been no reported increased risk of development or progression of diabetic retinopathy for insulin glargine compared with NPH insulin ([@b78-ce-2-089]; [@b43-ce-2-089]).

### Bodyweight

Good nutritional balance, paying particular attention to bodyweight, is a prerequisite for optimal treatment programs in patients with type 1 and type 2 diabetes mellitus. Unfortunately, in patients with type 2 diabetes, obesity is a common underlying problem and such patients frequently fail to adhere to dietary control and exercise programs/recommendations. Consequently, it is important to monitor changes in bodyweight to minimize possible cardiovascular risk. Weight gain is a common problem associated with insulin replacement therapy ([@b10-ce-2-089]). In the case of insulin glargine, changes in bodyweight reported in clinical trials were generally small with no clinically significant differences between insulin glargine and NPH insulin in patients with type 2 diabetes. In two large studies involving a total of \>10 000 patients with type 2 diabetes, insulin glargine for 24 weeks resulted in an increase in mean bodyweight of between 1 and 2 kg ([@b16-ce-2-089]; [@b52-ce-2-089]). A similar finding was documented following 1 year of treatment with insulin glargine (+2.12 kg vs baseline) in patients with type 2 diabetes ([@b59-ce-2-089]). Interestingly, with continued treatment for at least a further 28 months no further increase in bodyweight was observed (+2.02 kg vs baseline) ([@b49-ce-2-089]). In contrast, in an observational study undertaken in Germany involving \>12 000 patients suboptimally treated with oral antidiabetic drugs, body mass index decreased slightly in patients treated with insulin glargine compared with those who continued titration with oral therapy.

### Insulin antibodies

A possible concern with the administration of a foreign protein such as insulin glargine is the potential to induce an immunogenic response. However, none of the studies (16 weeks to \>3 years) that assessed antibody levels showed any evidence of such a reaction ([@b71-ce-2-089]; [@b78-ce-2-089]; [@b81-ce-2-089]; [@b105-ce-2-089]; [@b87-ce-2-089]; [@b91-ce-2-089]; [@b42-ce-2-089]; [@b59-ce-2-089]; [@b43-ce-2-089]; [@b49-ce-2-089]).

The majority of these clinical trials reported a similar lack of effect for insulin glargine and NPH insulin on antibody titers. However, four trials reported that insulin glargine was potentially less immunogenic than NPH insulin ([@b78-ce-2-089]; [@b105-ce-2-089]; [@b87-ce-2-089]; [@b59-ce-2-089]). In the longest study, insulin glargine administered for ≥28 months did not increase mean insulin glargine antibody levels or mean human insulin antibody levels following an initial 52-week comparative study. Indeed, with time, antibody levels slightly decreased ([@b49-ce-2-089]).

Economic evidence
=================

Economic assessments in diabetes can take a variety of perspectives depending on the type of patient, the healthcare system/country involved, the scientific/economic question being tested, and the type of study (RCT vs everyday practice). With regards to interpretation of such studies it is important to recognize that findings from one healthcare system may not necessarily apply to a different healthcare system. In most clinical scenarios the RCT is the benchmark for establishing scientific "best evidence," and there has been a tendency for health economists to use such trials to perform economic evaluations. However, the rigidity of RCTs creates limitations with respect to representing "real world" everyday practice. In such situations observational studies involving large cohorts of patients using the test products on a day-by-day basis provides valuable information about drug usage and its impact on patients outside the artificial confines of a clinical trial ([@b21-ce-2-089]). For insulin glargine a number of RCTs and observational economic studies have recently been published ([Table 9](#t9-ce-2-089){ref-type="table"}).

Type 1 diabetes mellitus
------------------------

[@b60-ce-2-089] compared insulin glargine with NPH insulin using a sophisticated model incorporating risk factors from major clinical trials such as the DCCT trial and Framingham studies. Based on two possible clinical scenarios (reduced hypoglycemia or reduced HbA~1c~), cost and health outcomes for a cohort of 10 000 patients treated for 40 years were forecast. This model demonstrated significant benefits for insulin glargine and the incremental cost effectiveness was found to be similar to that presented in the original NICE submission, thus reaffirming the overall value for money of insulin glargine and the significant health benefits that it provides. Comparable results from a Canadian payer perspective were reported by [@b32-ce-2-089] ([Table 9](#t9-ce-2-089){ref-type="table"}).

The two remaining economic analyses with insulin glargine in patients with type 1 diabetes were comparisons with insulin detemir---one in the US and one in the UK---and produced very divergent results.

[@b100-ce-2-089] in the US applied economic data to a single RCT in which insulin detemir was found to produce significantly less hypoglycemia than insulin glargine. Costs applied to a Center for Outcomes Research (CORE) diabetes model highlighted significant health economic advantages for insulin detemir. In comparison with insulin glargine, insulin detemir increased quality-adjusted life expectancy by 0.063 quality-adjusted life-years (QALYs), and reduced both direct and indirect medical costs. In contrast [@b74-ce-2-089] in the UK reported that the total cost of treatment was 10% lower for insulin glargine compared with insulin detemir (£132/patient per year; *P*\<0.001). These data were derived from an observational study involving type 1 diabetic patients treated for at least 6 months with insulin glargine or insulin detemir and who were included on the THIN database. Data were extracted from the same time period to avoid biases occurring as a result of changes in the rapidly evolving nature of diabetes-related clinical practice. Interestingly, the cost of hypoglycemia rescue medication was 25% lower with insulin glargine (*P*=0.052). Overall the authors calculated that based on these findings, treating 1000 patients for 1 year with insulin glargine would save £132 000 compared with insulin detemir.

[@b102-ce-2-089] assessed the economic evaluation presented with the original NICE submission of insulin glargine and published revised cost-effectiveness figures. They recognize that the model is highly sensitive to clinical assumptions such as the amount of utility gained by reducing patients' fear of hypoglycemia. Overall they concluded that compared with NPH insulin, insulin glargine is effective in reducing the incidence of nocturnal hypoglycemia, but since there does not appear to be any improvement in long-term glycemic control, insulin glargine is unlikely to reduce the incidence of long-term microvascular and cardiovascular complications associated with the disease. This latter conclusion can be questioned based on more recent findings with more aggressive treatment algorithms, and it will be interesting to see whether longer-term therapy with insulin glargine can impact microvascular/cardiovascular endpoints beyond that achieved with conventional insulins.

Type 2 diabetes mellitus
------------------------

[@b60-ce-2-089] compared insulin glargine with NPH insulin using a sophisticated model incorporating evidence from the UK Prospective Diabetes Study to simulate disease progression, data from the THIN database for patient characteristics, and appropriate outcomes results from pivotal clinical trials. The incremental cost-effectiveness ratio for insulin glargine versus NPH insulin was £10 027/QALY in one model (based on hypoglycemia) and £13 921/QALY in another (based on HbA~1c~); consistently below the £20 000/QALY considered cost effective by NICE. The authors concluded that compared with NPH, insulin glargine was highly cost effective and provides excellent value for money for the treatment of type 2 diabetes in the UK. These findings were reinforced by [@b32-ce-2-089] who undertook a similar analysis, but from a payer perspective, in Canada ([Table 9](#t9-ce-2-089){ref-type="table"}). [@b74-ce-2-089], again using observational data from the THIN database, reported that in type 2 diabetics the median cost for antidiabetic therapy was 28.1% lower in patients treated with insulin glargine compared with those treated with insulin detemir (£1014 vs £1410/patient per year; *P*\<0.001).

[@b9-ce-2-089] in the US reported that type 2 diabetic patients recently starting glargine therapy had a lower rate of hypoglycemia than patients using fixed-dose insulin combination products (7 vs 13.8 patients/year; *P*=0.027) and calculated that treatment of 15 patients with insulin glargine would avoid one hypoglycemic event per year compared with the premixed combination insulins.

In a US study long-term treatment with biphasic aspart Mix 30 in insulin-naïve type 2 diabetic patients as part of a triple-therapy regimen was more cost effective than insulin glargine, with an incremental cost-effectiveness ratio of \$US46 533 per QALY. The authors acknowledge the limitations of the clinical trial which was of short duration and included a relatively young cohort of patients ([@b82-ce-2-089]). [@b53-ce-2-089] found that total daily costs were similar for insulin glargine and conventional insulins, although the glargine group used significantly lower doses of insulin and required fewer blood glucose test strips.

Finally, in two clinical trials the total cost of achieving glycemic control was lower for insulin glargine than for rosiglitazone ([@b89-ce-2-089]) or pioglitazone ([@b63-ce-2-089]) as add-on therapy in patients with type 2 diabetes poorly controlled with oral therapy.

Clinical value
==============

Diabetes mellitus is a chronic disease associated with high morbidity and mortality as a result of microvascular and macrovascular complications. Today it represents a major public health concern of almost epidemic proportions and this picture is forecast to worsen as patient populations become older and are associated with a greater prevalence of risk factors ([@b11-ce-2-089]; [@b76-ce-2-089]). This will increase the burden on health services, which are already under pressure. It almost goes without saying that any intervention that can improve patient care and reduce clinic/hospital visits will not only relieve some of this burden, it will also likely have a positive impact on patient QOL and wellbeing.

The Diabetes Control and Complications Trial ([@b17-ce-2-089]) provided convincing evidence that tight and sustained management of glycemia using an intensive therapy regimen and regular follow-up/monitoring, reduces both the development and progression of microvascular complications. These findings form the basis for most treatment guidelines used in the care of diabetic patients. One of the biggest challenges facing the physician and patient when using intensive insulin regimens is to achieve optimal glycemic control without provoking episodes of hypoglycemia which could potentially be fatal.

Hypoglycemia is thought to occur at times corresponding with peak plasma insulin concentrations, and insulin glargine with its relatively flat plasma concentration-versus-time profile, with no pronounced peaks over 24 hours, may therefore have an advantage. It might also facilitate a more physiologic approach to diabetes management with basal insulin glargine providing a constant level of insulin throughout the day, and bolus insulin being used to provide prandial cover.

In the setting of type 1 diabetes, basal/bolus treatment with insulin glargine (once daily) has proven to be at least as effective as conventional once- or twice- daily treatment with NPH insulin with a trend toward less hypoglycemia. This evidence was reviewed by NICE in the UK ([@b67-ce-2-089]) which concluded:

"On the balance of effectiveness and cost-effectiveness evidence, insulin glargine, which has a peakless action profile, is also recommended as a long-acting preparation for people with type 1 diabetes; some studies in this review show significantly lower FBG with insulin glargine than isophane (NPH) insulin and others suggest that people on insulin glargine may experience fewer hypoglycemic events than people receiving once-daily isophane (NPH) insulin."

More recent clinical trials have confirmed these findings in studies of long duration and added to our understanding of the value of insulin glargine showing that: it can be administered at other times of the day with equal effect (the initial recommendation was for it to be given at bedtime)it is effective and well tolerated in children and adolescentsit is a suitable replacement for continuous subcutaneous insulin infusions during pump-free periods associated with pump malfunction, adverse effects, or physical activity.

Type 2 diabetes has traditionally been treated in a stepwise manner with lifestyle modifications such as diet and exercise being a cornerstone of day-to-day management. If this fails to achieve the desired level of glycemic control, then oral antidiabetic drugs can be introduced (alone or in combination). Insulin has generally only been considered if the above steps fail. Insulin glargine has been studied in a number of large clinical trials involving patients poorly controlled by lifestyle changes and oral antidiabetic therapy, and it was shown to be at least as effective as NPH insulin with the clinically important advantage of causing significantly fewer episodes of nocturnal hypoglycemia.

Economic analyses with insulin glargine have confirmed the findings of the original NICE assessment, and economic models applied to UK and Canadian healthcare systems have demonstrated its cost effectiveness relative to NPH insulin in patients with type 1 and type 2 diabetes. Equally important, a number of studies have shown that insulin glargine has a positive impact on patient satisfaction, wellbeing, and other measures of QOL. In this regard it was shown to be significantly superior to NPH insulin in type 1 diabetes, and to pioglitazone and rosiglitazone in type 2 diabetes.

In summary, there is now a wealth of evidence, including official recommendations, well-controlled clinical trials, and large observational studies in everyday practice highlighting the suitability of insulin glargine as a first-line choice as a basal insulin replacement in patients with type 1 diabetes mellitus, including children and adolescents. There is also convincing evidence for its efficacy and safety in patients with type 2 disease who require insulin treatment to achieve glycemic control.

Future studies should be directed toward establishing the efficacy and safety of insulin glargine in the long term since it is a life-long therapy for most patients. It will also be interesting to see whether the potential for more intense glycemic control correlates with a significant delay in the progression of microvascular/macrovascular complications and improves long-term survival rates. Results from long-term studies assessing cardiovascular risk/outcomes in large cohorts of patients, such as ORIGIN ([@b95-ce-2-089]) and HEART2D ([@b64-ce-2-089]) are awaited with interest.

The authors declare that they have no conflict of interest.

![Diagramatic representation of the glycodynamic activity profile of insulin glargine and NPH insulin (as determined by GIR, based on results from euglycemic clamp studies) after administration of 0.4 U/kg to healthy volunteers ([@b38-ce-2-089]) and 0.3 U/kg to patients with type 1 diabetes ([@b54-ce-2-089]). GIR, glucose infusion rate; NPH, neutral protamine hagedorn.](ce-2-089f1){#f1-ce-2-089}

###### 

Evidence base included in the review

  **Category**                                                   **Number**
  -------------------------------------------------------------- ------------
  Initial search                                                 59
    records excluded                                             14
    records included                                             45
  Additional studies identified                                  4
  Search update, new records                                     41
    records excluded                                             17
    records included                                             24
  Level 1 clinical evidence (systematic review, meta analysis)   1
  Level 2 clinical evidence (RCT)                                59
  Level ≥3 clinical evidence                                     6
    trials other than RCT                                        6
    case reports                                                 0
  Economic evidence                                              7
  Total records included                                         73

For definition of levels of evidence, see Editorial Information on inside back cover.

RCT, randomized controlled trial.

###### 

Commonly used human and analog insulins (adapted from [@b77-ce-2-089]; [@b34-ce-2-089]; [@b2-ce-2-089])

  **Generic name**                                  **Brand name**              **Form**
  ------------------------------------------------- --------------------------- --------------------------
  **Rapid-acting**                                  **Onset: within 15 mins**   **Duration: up to 4 h**
  Insulin aspart                                    Novolog, NovoRapid          Analog
  Insulin glulisine                                 Apidra                      Analog
  Insulin lispro                                    Humalog                     Analog
  **Short-acting**                                  **Onset: within 1 h**       **Duration: up to 18 h**
  Regular human insulin                             Humulin R, Novolin R        Human
  **Biphasic insulin analogs**                      **Onset: 5--45 min**        **Duration: 10--16 h**
  Insulin lispro 25%/insulin lispro protamine 75%   HumalogMix 25               Analog
  Insulin lispro 50%/insulin lispro protamine 50%   HumalogMix 50               Analog
  Insulin aspart 30%/insulin aspart protamine 70%   NovoMix 30                  Analog
  **Intermediate-acting**                           **Onset: 2--4 h**           **Duration: 10--16 h**
  Human NPH insulin                                 Humulin N, Novolin N        Human
  **Long-acting**                                   **Onset: 2--4 h**           **Duration: up to 24 h**
  Insulin detemir                                   Levemir                     Analog
  Insulin glargine                                  Lantus                      Analog

NPH, neutral protamine hagedorn.

###### 

Level 2 evidence of glycemic control in patients with type 1 diabetes mellitus treated with once-daily insulin glargine or once- or twice-daily NPH insulin as part of a basal/bolus regimen. All studies were open-label, randomized, multicenter, and included \>100 patients per treatment group

  **Study**                         **Treatment**           **Study duration**   **Change from baseline to endpoint**   **Insulin dose**   **Frequency of hypoglycemia (% patients)**                                                                                                                                                                      
  --------------------------------- ----------------------- -------------------- -------------------------------------- ------------------ ------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------ ------ ------ ------
  **Studies in adults**                                                                                                                                                                                                                                                                                                                                    
  [@b78-ce-2-089]                   IG once daily (n=310)   16 weeks             −1.7                                   −2.2               −0.1                                                                                             −4.5 U[a](#tfn4-ce-2-089){ref-type="table-fn"}; +1.5 U[b](#tfn5-ce-2-089){ref-type="table-fn"}   90.6   69.0   6.5
  NPH once or twice daily (n=309)                           −0.6                 −0.7                                   −0.1               +0.9 U[a](#tfn4-ce-2-089){ref-type="table-fn"}; −0.5 U[b](#tfn5-ce-2-089){ref-type="table-fn"}   90.6                                                                                             63.1   5.2    
  *P*=0.0001                        *P*=0.0001              *P*=NS               *P*=NS                                 *P*=NS             *P*=NS                                                                                           *P*=NS                                                                                                         
  [@b81-ce-2-089]                   IG once daily (n=264)   28 weeks             −1.12                                  −1.67              −0.16                                                                                            −5 U[a](#tfn4-ce-2-089){ref-type="table-fn"}; +3.9 U[b](#tfn5-ce-2-089){ref-type="table-fn"}     39.9   18.2   1.9
  NPH once or twice daily (n=270)                           −0.94                −0.33                                  −0.21              +1.8 U[a](#tfn4-ce-2-089){ref-type="table-fn"}; +1.7 U[b](#tfn5-ce-2-089){ref-type="table-fn"}   49.2                                                                                             27.1   5.6    
  *P*=NS                            *P*=0.01                *P*=NS                                                      *P*\<0.05          *P*\<0.05                                                                                        *P*=NS                                                                                                         
  [@b40-ce-2-089]                   IG once daily (n=195)   28 weeks             −1.17                                  ND                 −0.09                                                                                            −7.1 U[a](#tfn4-ce-2-089){ref-type="table-fn"}; +6.1 Ub                                          73.3   71.2   2.6
  NPH twice daily (n=199)                                   −0.56                ND                                     −0.19              −2.3 U[a](#tfn4-ce-2-089){ref-type="table-fn"}; +1.0 Ub                                          81.7                                                                                             69.5   5.1    
  *P*=0.02                                                  *P*=NS                                                      *P*=0.02           *P*=NS                                                                                           *P*=NS                                                                                                         
  [@b43-ce-2-089]                   IG once daily (n=292)   28 weeks             −1.17                                  −0.82              0.21                                                                                             −2.0 U[c](#tfn6-ce-2-089){ref-type="table-fn"}                                                   89.0   61.0   10.6
  NPH once or twice daily (n=293)                           −0.89                −0.79                                  0.10               0                                                                                                84.6                                                                                             61.1   15.0   
  *P*=NS                            *P*=NS                  *P*=NS               *P*=NS                                 *P*=NS             *P*=NS                                                                                           *P*=NS                                                                                                         
  **Study in children**                                                                                                                                                                                                                                                                                                                                    
  [@b91-ce-2-089]                   IG once daily (n=174)   28 weeks             −1.29                                  ND                 0.28                                                                                             −1.3 U[a](#tfn4-ce-2-089){ref-type="table-fn"}                                                   79.3   48     23.0
  NPH once or twice daily (n=175)                           −0.68                ND                                     0.27               +2.4 U[a](#tfn4-ce-2-089){ref-type="table-fn"}                                                   78.9                                                                                             52     28.6   
  *P*=0.02                                                  *P*=NS                                                      *P*=NS             *P*=NS                                                                                           *P*=NS                                                                                                         

Basal dosage;

Preprandial dosage;

Total insulin dosage.

FBG, fasting blood glucose; FPG, fasting plasma glucose; HbA~1c~, glycosylated hemoglobin; IG, insulin glargine; NPH, neutral protamine hagedorn; NS, nonsignificant; ND, no details provided.

###### 

Level 2 evidence of glycemic control in patients with type 2 diabetes mellitus treated with once-daily insulin glargine or once- or twice-daily NPH insulin in combination with oral antidiabetic drugs (except for [@b87-ce-2-089], in which regular human insulin premeals was maintained). All studies were randomized, multicenter, of open-label design, and included \>200 patients per treatment group

  **Study**                            **Treatment**           **Study duration**                             **Change from baseline to endpoint**           **Insulin dose**   **Frequency of hypoglycemia (% patients)**                                                                                                                                                              
  ------------------------------------ ----------------------- ---------------------------------------------- ---------------------------------------------- ------------------ ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------- ---------------------------------------------- --------------------------------------------
  [@b84-ce-2-089]                      IG o.n. (n=367)         24 weeks                                       ND                                             −4.5               −1.65                                                47.2 U                                               13.9[a](#tfn8-ce-2-089){ref-type="table-fn"}   4.0[a](#tfn8-ce-2-089){ref-type="table-fn"}    2.5
  NPH o.n. (n=389)                                             ND                                             −4.1                                           −1.59              41.8 U                                               17.7[a](#tfn8-ce-2-089){ref-type="table-fn"}         6.9[a](#tfn8-ce-2-089){ref-type="table-fn"}    1.8                                            
                                       *P*=NS                  *P*=NS                                         *P*=0.005                                      *P*\<0.02          *P*\<0.001                                           *P*=NS                                                                                                                                             
  [@b87-ce-2-089]                      IG o.n. (n=259)         28 weeks                                       −1.3[b](#tfn9-ce-2-089){ref-type="table-fn"}   ND                 −0.41                                                0.75 U/kg[c](#tfn10-ce-2-089){ref-type="table-fn"}   61.4                                           31.3                                           ND
  NPH o.n., or o.n. and o.m. (n=259)                           −1.2[b](#tfn9-ce-2-089){ref-type="table-fn"}   ND                                             −0.59              0.75 U/kg[c](#tfn10-ce-2-089){ref-type="table-fn"}   66.8                                                 40.2                                           ND                                             
  *P*=NS                                                       *P*=NS                                         *P*=NS                                         *P*\<0.05          *P*\<0.02                                                                                                                                                                                               
  [@b23-ce-2-089]                      IG once daily (n=231)   24 weeks                                       −4.8                                           ND                 −1.38                                                32.6 U                                               52.8                                           20.4                                           2.6
  NPH once daily (n=250)                                       −4.1                                           ND                                             −1.44              31.2 U                                               62.8                                                 34.8                                           4.4                                            
  *P*=NS                                                       *P*=NS                                         *P*=NS                                         *P*=0.042          *P*\<0.001                                           *P*=0.303                                                                                                                                          
  [@b26-ce-2-089]                      IG o.m. (n=236)         28 weeks                                       −5.1                                           ND                 −1.24[d](#tfn11-ce-2-089){ref-type="table-fn"}       40 U                                                 56                                             17[f](#tfn13-ce-2-089){ref-type="table-fn"}    2.1
  IG o.n. (n=227)                                              −5.2                                           ND                                             −0.96              37 U                                                 43[e](#tfn12-ce-2-089){ref-type="table-fn"}          23[f](#tfn13-ce-2-089){ref-type="table-fn"}    1.8                                            
  NPH o.n. (n=293)                                             −5.3                                           ND                                             −0.84              39 U                                                 58                                                   38                                             2.6                                            
  *P*=NS                                                                                                      *P*=NS                                                            *P*\<0.001                                           *P*\>0.2                                                                                                                                           
  [@b105-ce-2-089]                     IG o.n. (n=214)         52 weeks                                       ND[g](#tfn14-ce-2-089){ref-type="table-fn"}    ND                 −0.76                                                23 U                                                 33[b](#tfn9-ce-2-089){ref-type="table-fn"}     9.9                                            0
  NPH o.n. (n=208)                                             ND[g](#tfn14-ce-2-089){ref-type="table-fn"}    ND                                             −0.66              21 U                                                 42[b](#tfn9-ce-2-089){ref-type="table-fn"}           24                                             0                                              
  *P*=NS                                                       *P*=0.04                                       *P*\<0.001                                     *P*=NS                                                                                                                                                                                                                     
  [@b59-ce-2-089]                      IG o.n. (n=289)         52 weeks                                       −2.7                                           −2.8               −0.46                                                ND                                                   32.5                                           9.5                                            1.7
  NPH o.n. (n=281)                                             −2.6                                           −2.7                                           −0.38              ND                                                   37.3                                                 22.2                                           1.1                                            
  *P*=0.26                             *P*=0.65                *P*=0.415                                                                                     *P*=NS             *P*=0.0006                                           *P*=NS                                                                                                                                             
  [@b69-ce-2-089]                      IG o.n. (n=220)         24 weeks                                       −5.8                                           ND                 −0.99                                                22 U                                                 515[h](#tfn15-ce-2-089){ref-type="table-fn"}   221[h](#tfn15-ce-2-089){ref-type="table-fn"}   5[h](#tfn15-ce-2-089){ref-type="table-fn"}
  NPH o.n. (n=223)                                             −5.7                                           ND                                             −0.77              23 U                                                 908[h](#tfn15-ce-2-089){ref-type="table-fn"}         620[h](#tfn15-ce-2-089){ref-type="table-fn"}   28[h](#tfn15-ce-2-089){ref-type="table-fn"}    
  *P*=NS                                                       *P*=0.032                                      *P*=NS                                         *P*=0.0003         *P*=0.001                                            *P*\<0.03                                                                                                                                          

Events per patient-year;

Estimated from a graphical presentation;

Total insulin dosage, basal + bolus;

*P*\<0.001 vs NPH insulin and *P*=0.008 vs IG at bedtime;

*P*=0.001 vs NPH insulin and *P*=0.004 vs IG in the morning;

*P*\<0.001 vs NPH insulin;

Glycemic control was equivalent for the two groups;

Number of episodes of hypoglycemia.

FBG, fasting blood glucose; FPG, fasting plasma glucose; HbA~1c~, glycosylated hemoglobin; IG, insulin glargine; NPH, neutral protamine hagedorn; ND, no details provided; NS, nonsignificant; o.m., in the morning; o.n., at night (bedtime).

###### 

Meta analysis of four randomized, open-label, clinical trials comparing insulin glargine (n=1142) with NPH insulin (n=1162) in patients with type 2 diabetes poorly controlled by oral antidiabetic drugs \[or receiving preprandial regular human insulin ([@b87-ce-2-089])\] ([@b88-ce-2-089])

  **Outcome measure**                                   **Insulin glargine (n=1142)**   **NPH insulin (n=1162)**   ***P*value**
  ----------------------------------------------------- ------------------------------- -------------------------- --------------
  **Patients with HbA**~**1c**~**≤7.0% (% patients)**                                                              
  At baseline                                           3.1                             3.3                        *P*=NS
  At endpoint                                           30.8                            32.1                       *P*=NS
  **Fasting plasma glucose (mmol/L)**                                                                              
  At baseline                                           11                              11                         *P*=NS
  At endpoint                                           8                               9                          *P*=0.023
  **Basal insulin dosage (U)**                                                                                     
  At baseline                                           21                              21                         *P*=NS
  At endpoint                                           38                              37                         *P*=NS
  **Symptomatic hypoglycemia (% patients)**                                                                        
  Overall documented                                    54.2                            61.2                       *P*=0.0006
  Nocturnal documented                                  28.4                            38.2                       *P*\<0.0001
  Nonnocturnal documented                               49.6                            51.7                       *P*=0.4642
  Severe documented                                     1.4                             2.6                        *P*=0.0442
  Severe nocturnal documented                           0.7                             1.7                        *P*=0.0231
  Severe nonnocturnal documented                        0.8                             0.9                        *P*=0.7296

HbA~1c~, glycosylated hemoglobin; NPH, neutral protamine hagedorn; NS, nonsignificant.

###### 

Level 2 evidence of glycemic control in patients with type 2 diabetes mellitus poorly controlled on previous therapy, comparing insulin glargine and premixed biphasic insulins over a period of 16--28 weeks

  **Reference**                                                                                                                                              **Treatment**                                                    **Change from baseline**                        **Insulin dose**   **Hypoglycemia**                                **Pts achieving blood glucose target of \<5.6--7.0 mmol/L (%)**   **Pts achieving HbA**~**1c**~**level \<7%**                                                   
  ---------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- ----------------------------------------------- ------------------ ----------------------------------------------- ----------------------------------------------------------------- ----------------------------------------------- --------------------------------------------- ------
  [@b47-ce-2-089]                                                                                                                                            IG once daily[a](#tfn18-ce-2-089){ref-type="table-fn"} (n=177)   −3.1                                            −1.64              +18.3 U                                         2.62[c](#tfn20-ce-2-089){ref-type="table-fn"}                     0.51[c](#tfn20-ce-2-089){ref-type="table-fn"}   31.6                                          49.4
  Premixed human insulin 30/70 twice daily[b](#tfn19-ce-2-089){ref-type="table-fn"} (n=187)                                                                  −2.2                                                             −1.31                                           +43.9 U            5.73[c](#tfn20-ce-2-089){ref-type="table-fn"}   1.04[c](#tfn20-ce-2-089){ref-type="table-fn"}                     15.0                                            31.0                                          
  *P*=0.0001                                                                                                                                                 *P*=0.0003                                                                                                       *P*=0.0009         *P*=0.045                                       *P*=0002                                                          *P*=0.06                                                                                      
  [@b79-ce-2-089]                                                                                                                                            IG once daily[d](#tfn21-ce-2-089){ref-type="table-fn"} (n=116)   125[e](#tfn22-ce-2-089){ref-type="table-fn"}    −2.36              +0.42 U/kg                                      0.7[f](#tfn23-ce-2-089){ref-type="table-fn"}                      ND                                              57[g](#tfn24-ce-2-089){ref-type="table-fn"}   40
  Biphasic insulin aspart 30/70 twice daily (n=117)                                                                                                          125[e](#tfn22-ce-2-089){ref-type="table-fn"}                     −2.79                                           +0.68 U/kg         3.4[f](#tfn23-ce-2-089){ref-type="table-fn"}    ND                                                                36[g](#tfn24-ce-2-089){ref-type="table-fn"}     66                                            
  *P*=NS                                                                                                                                                     *P*\<0.01                                                        *P*\<0.05                                       *P*\<0.05                                                                                                                            *P*\<0.001                                                                                    
  [@b50-ce-2-089]                                                                                                                                            IG once daily (n=127) + glimepiride                              −2.2[h](#tfn25-ce-2-089){ref-type="table-fn"}   −0.2               ND                                              9.0                                                               ND                                              ND                                            26.2
  Biphasic insulin aspart 30/70 twice daily (n=128) + metformin                                                                                              −2.6[h](#tfn25-ce-2-089){ref-type="table-fn"}                    −0.5                                            ND                 20.3                                            ND                                                                ND                                              33.1                                          
  *P*=0.23                                                                                                                                                   *P*=0.0002                                                                                                       *P*=0.012                                                                                                                            *P*=0.27                                                                                      
  [@b56-ce-2-089]                                                                                                                                            IG once daily[i](#tfn26-ce-2-089){ref-type="table-fn"} (n=53)    −1.61                                           −0.9               +0.18 U/kg                                      0.39[k](#tfn28-ce-2-089){ref-type="table-fn"}                     12                                              65                                            18
  Biphasic insulin lispro 25/75 twice daily[j](#tfn27-ce-2-089){ref-type="table-fn"} (n=52)                                                                  −0.75                                                            −1.3                                            +0.23 U/kg         0.68[k](#tfn28-ce-2-089){ref-type="table-fn"}   11                                                                45                                              42                                            
  *P*\<0.001                                                                                                                                                 *P*=0.003                                                        *P*=0.001                                       *P*=0.041          *P*=NS                                          *P*=0.019                                                         *P*\<0.001                                                                                    
  [@b57-ce-2-089]                                                                                                                                            IG once daily[i](#tfn26-ce-2-089){ref-type="table-fn"} (n=47)    −1.03                                           −0.42              +0.09 U/kg                                      0.44                                                              0.34                                            51                                            12
  Biphasic insulin lispro 25/75 twice daily[j](#tfn27-ce-2-089){ref-type="table-fn"} (n=50)                                                                  −0.52                                                            −1.00                                           +0.15 U/kg         0.61                                            0.14                                                              34                                              30                                            
  *P*=0.007                                                                                                                                                  *P*\<0.001                                                       *P*\<0.001                                      *P*=0.477          *P*\<0.002                                      *P*=0.01                                                          *P*=0.002                                                                                     
  [@b46-ce-2-089]                                                                                                                                            IG once daily[d](#tfn21-ce-2-089){ref-type="table-fn"} (n=60)    ND                                              −0.75                                                              2.57                                                              0.80                                            ND                                            31
  Biphasic insulin lispro 50/50 before breakfast and lunch and biphasic insulin lispro 25/75 before dinner (n=60)[l](#tfn29-ce-2-089){ref-type="table-fn"}   ND                                                               −1.01                                                              3.98                                            1.05                                                              ND                                              44                                            
  *P*=0.008                                                                                                                                                                                                                   *P*=0.001                                       *P*=0.36                                                           *P*=0.103                                                                                                                                                       

In the morning in combination with glimepiride and metformin;

Without oral antidiabetic drugs;

Mean number of events/patient per year;

At bedtime in combination with oral antidiabetic drugs;

Decrease in FPG in mg/dL;

Incidence of minor hypoglycemic events/patient per year;

Patients achieving a target FPG of 80--110 mg/dL;

FPG;

At bedtime in combination with metformin;

In combination with metformin;

Overall rate of hypoglycemia (events/patient/30 days);

Crossover study.

FBG, fasting blood glucose; HbA1c, glycosylated hemoglobin; IG, insulin glargine; ND, no details provided; NS, nonsignificant; pts, patients.

###### 

Summary of safety data from a large clinical trial involving \>7000 patients with type 2 diabetes treated with insulin glargine for 24 weeks ([@b52-ce-2-089])

  **No. of patients**                                 **Study group**
  --------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------
  7893                                                Adults with type 2 diabetes treated with insulin glargine
  7605 (96.4%)                                        Safety population \[7893: patients with no data (n=169) or who did not receive treatment (n=119)\]
  2737 (35%)                                          Reported at least one AE related to treatment
  751 (10%)                                           Reported one AE that was assessed as being possibly related to insulin glargine
  642 (8%)[a](#tfn31-ce-2-089){ref-type="table-fn"}   Reported at least one AE that was classified as serious
  129 (1.7%)                                          Serious AEs assessed as being possibly related to insulin glargine and of these only hypoglycemia occurred in \>0.1% of patients
  35 (0.5%)                                           Deaths; the majority due to cardiovascular events and none were assessed as being caused by insulin glargine

Serious AEs reported by \>0.1% of patients were hypoglycemia (2.1%); cardiac failure (0.6%); chest pain (0.5%); coronary artery disease (0.5%); cellulitis (0.4%); pneumonia (0.4%); myocardial infarction (0.3%); transient ischemic attacks (0.2%); cerebrovascular accident (0.2%). Ninety-five patients (1.2%) discontinued treatment because of a serious AE.

AE, adverse event.

###### 

Safety profile in patients with type 2 diabetes treated with insulin glargine or NPH insulin for 1 year ([@b59-ce-2-089])

  **Safety parameter**                **Insulin glargine (n=289)**                     **NPH insulin (n=281)**
  ----------------------------------- ------------------------------------------------ -------------------------
  At least one AE                     65%                                              65%
  AE possibly related to medication   5.5%                                             7.5%
  Injection site reactions            2.4%                                             3.2%
  Metabolic/nutritional AE            1.7%                                             2.5%
  Change in bodyweight                +2.01 kg                                         +1.88 kg
  Antibodies against IG               +0.9%[a](#tfn33-ce-2-089){ref-type="table-fn"}   +5.9%
  Antibodies against NPH              +0.5%[a](#tfn33-ce-2-089){ref-type="table-fn"}   +6.3%

Statistically significant difference between IG and NPH.

AE, adverse event; IG, insulin glargine; NPH, neutral protamine hagedorn.

###### 

Summary of economic studies involving insulin glargine in the treatment of patients with type 1 and type 2 diabetes mellitus

  **Reference**                                      **Country/healthcare system**     **Economic objective**                                                                                                        **Economic model**                                                                                                                                                                                          **Results and conclusions**
  -------------------------------------------------- --------------------------------- ----------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Assessments in patients with type 1 diabetes**                                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                 
  [@b60-ce-2-089]                                    UK/NHS                            CE/CU comparison of IG and NPH insulin                                                                                        Simulated outcomes model using DCCT and Framingham data with meta analysis of RCT of IG vs NPH results                                                                                                      The incremental CE ratio for IG vs NPH insulin ranged from £2695 to £10 943; consistently below the £20 000/QALY considered cost effective by the NHS. Compared with NPH, IG was highly cost effective and provided significant health benefits
  [@b32-ce-2-089]                                    Canada/public payer perspective   CE/CU comparison of IG and NPH insulin                                                                                        Simulated outcomes model to which results from a RCT of IG vs NPH were incorporated                                                                                                                         IG resulted in greater life-years gained (0.21--0.24) and QALYs (0.17--0.2) compared with NPH. The weighted incremental cost per life-year and QALY gained were \$Can18 661 and \$Can20 799. These data provide strong support for the adoption of IG from a Canadian payer view
  [@b74-ce-2-089]                                    UK/NHS                            Prescription costs and total cost of treatment or IG and ID                                                                   Analysis of treatment costs (drugs, reagents, syringes, sharps, hypoglycemia rescue medication) for patients treated with IG (n=625) or ID (n=268), THIN data                                               The volume of IG prescribed was consistently lower with IG than with ID and the total cost of treatment was 10% lower for IG compared with ID (£132/patient per year; *P*\<0.001)
  [@b100-ce-2-089]                                   US/Medicare                       CE/CU comparison of IG and ID                                                                                                 CORE Diabetes Model incorporating clinical data from a single RCT of IG vs ID                                                                                                                               Compared with IG, ID increased quality-adjusted life expectancy by 0.063 QALYS, and reduced direct medical costs by \$US2072 and indirect costs by \$US3103
                                                                                                                                                                                                                                                                                                                                                                                                                                 
  **Assessments in patients with type 2 diabetes**                                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                 
  [@b61-ce-2-089]                                    UK/NHS                            CE/CU comparison of IG and NPH insulin                                                                                        Simulated outcomes model using UKPDS study data, data from the THIN database and two meta analyses comparing IG vs NPH                                                                                      The incremental CE ratio for IG vs NPH insulin was £10 027/QALY in one model and £13 921/QALY in another; consistently below the £20 000/QALY considered cost effective by the NHS. Compared with NPH, IG was highly cost effective and provides excellent value for money for the treatment of type 2 diabetes in the UK
  [@b32-ce-2-089]                                    Canada/public payer perspective   CE/CU comparison of IG and NPH insulin                                                                                        Simulated outcomes model using UKPDS data to which results from a RCT of IG vs NPH were incorporated                                                                                                        IG resulted in greater life-years gained (0.52--0.59) and QALYs (0.48--0.52) compared with NPH. The weighted incremental cost per life-year and QALY gained were \$Can8041 and \$Can8618. These data provide strong support for the adoption of IG from a Canadian payer view
  [@b74-ce-2-089]                                    UK/NHS                            Prescription costs and total cost of treatment for IG and ID                                                                  Analysis of treatment costs (drugs, reagents, syringes, sharps, hypoglycemia rescue medication) for patients treated with IG (n=977) or ID (n=334), THIN data                                               In type 2 diabetics the median cost for antidiabetic therapy was 28.1% lower in patients treated with IG than in those treated with ID (£1014 vs £1410/patient per year; *P*\<0.001)
  [@b82-ce-2-089]                                    US/general practice               CE/CU comparison of IGand biphasic insulin aspart Mix 30                                                                      Costs applied to the INITIATE RCT (IG, n=116; Mix 30, n=117) and input into a validated Markov/Monte-Carlo simulation model                                                                                 This study suggests that long-term treatment with biphasic aspart Mix 30 in insulin-naïve type 2 diabetic patients as part of a triple-therapy regimen may have economic advantages over IG. The authors acknowledge the limitations of the clinical trial which was of short duration and included a relatively young cohort of patients
  [@b53-ce-2-089]                                    Austria/general practice          Total cost of treatment with IG and conventional insulins. Treatment and dosage were based on everyday practice               Simulated outcomes model using DCCT and Framingham data with meta analysis of RCT of IG vs NPH results                                                                                                      Observational study comparing IG with conventional insulin therapy to which appropriate costs were applied
  [@b9-ce-2-089]                                     US/general practice               Comparison of the cost of managing hypoglycemia in inpatients treated with IG or a premixed fixed dose combination product    An observational analysis involving patients treated with IG (n=1212) or a premixed fixed-dose combination product (n=1103) identified using a claims database. Cost of managing hypoglycemia in patients   Type 2 diabetic patients recently starting IG therapy had a lower rate of hypoglycaemia than patients using fixed-dose insulin combination products (7 vs 13.8 patients/year; *P*=0.027). The authors calculated that treatment of 15 patients with IG would avoid one hypoglycemic event per year compared with the premixed combination products
  [@b89-ce-2-089]                                    US/general practice               To compare the total cost of maintaining glycemic control in patients using IG or rosiglitazone in a triple therapy regimen   Cost analysis applied to a RCT comparing IG (n=105) and rosiglitazone (n=112) in triple therapy regimens                                                                                                    The cost of maintaining glycemic control was significantly lower with IG than with rosiglitazone (IG saved \$US235 over a period of 24 weeks). Furthermore the authors calculated that the mean cost per 1% reduction in HbA~1c~ was \$US824 for IG and \$US1062 for rosiglitazone; an important finding given that medical resource utilization may further decrease as a result of improved glycemic control
  [@b63-ce-2-089]                                    US/general practice               To compare the total cost of maintaining glycemic control in patients using IG or pioglitazone added to oral monotherapy      Cost analysis applied to a RCT comparing IG (n=118) and pioglitazone (n=112) as add-on therapy                                                                                                              IG added to monotherapy in patients with poorly controlled type 2 diabetes improved clinical outcomes such as glycemic control and quality of life. The estimated mean total cost of glycemic control over 48 weeks was \$US379 less for IG-treated patients (\$US1721 vs \$US2100 for pioglitazone)

CE, cost-effectiveness evaluation; CORE, Center for Outcomes Research; CU, cost-utility evaluation; DCCT, Diabetes Control and Complications Trial; ID, insulin detemir; IG, insulin glargine; NHS, National Health Service; NPH, neutral protamine hagedorn; OAD, oral antidiabetic drug; QALY, quality-adjusted life-year; RCT, randomized clinical trial; THIN, The Health Improvement Network; UKPDS, UK Prospective Diabetes Study.
